Edgewise Therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle.
Edgewise Therapeutics's mission is to develop new therapies for the treatment of patients with debilitating musculoskeletal disease using uncompromising standards of scientific rigor, personal integrity, and a deep respect for those whose lives we touch.
Edgewise Therapeutics was founded in 2017 by Alan Russell, Peter Thompson, and Badreddin Edris. The company has its headquarter based in Boulder, Colorado.
Edgewise Therapeutics is a new company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases.
Edgewise Therapeutics has built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease.
Edgewise Therapeutics is backed by Novo Holdings A/S, U.S. Venture Partners (USVP), OrbiMed Advisors, Deerfield Management, New Leaf Venture Partners, and Cure Duchenne Ventures. The company raised $50M from a "Series B" financing on Sep 17, 2019.